Related Experiment Video
Updated: Apr 26, 2026

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
Published on: June 14, 2016
Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment
Brendan N Putko1, Kevin Wen, Richard B Thompson
1Division of Cardiology, Department of Medicine, Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, T6G 2S2, AB, Canada.
Insights
Anderson-Fabry disease (AFD) is a genetic disorder causing globotriaosylceramide buildup. Early diagnosis and enzyme replacement therapy (ERT) can manage AFD cardiomyopathy, a major cause of mortality.
Area of Science:
- Genetics
- Biochemistry
- Cardiology
Background:
- Anderson-Fabry disease (AFD) is a rare X-linked lysosomal storage disorder.
- It results from deficient alpha-galactosidase A (α-Gal A) activity, leading to globotriaosylceramide accumulation.
- AFD cardiomyopathy is a significant cause of mortality in affected individuals.
Observation:
- Cardiac manifestations include structural, valvular, vascular, and conduction abnormalities.
- Prevalence studies show AFD affects diverse ethnic populations, highlighting a potential unrecognized health burden.
- Genetic testing is crucial for diagnosing AFD, especially in women.
Findings:
- Echocardiography with strain imaging and cardiac MRI (late enhancement, T1 mapping) are key diagnostic tools.
- Enzyme replacement therapy (ERT) can reverse or prevent disease progression.
- Gene therapy and molecular chaperones are emerging as novel therapeutic strategies.
Implications:
- Anderson-Fabry cardiomyopathy is a treatable cause of heart failure if diagnosed and managed early.
- Prompt initiation of ERT is critical for improving outcomes and preventing irreversible cardiac damage.
- Increased awareness and screening can help identify affected individuals and reduce mortality associated with AFD.
Abstract:
Anderson-Fabry disease (AFD) is a lysosomal storage disease caused by the inappropriate accumulation of globotriaosylceramide in tissues due to a deficiency in the enzyme α-galactosidase A (α-Gal A). Anderson-Fabry cardiomyopathy is characterized by structural, valvular, vascular and conduction abnormalities, and is now the most common cause of mortality in patients with AFD. Large-scale metabolic and genetic screening studies have revealed AFD to be prevalent in populations of diverse ethnic origins, and the variant form of AFD represents an unrecognized health burden. Anderson-Fabry disease is an X-linked disorder, and genetic testing is critical for the diagnosis of AFD in women. Echocardiography with strain imaging and cardiac magnetic resonance imaging using late enhancement and T1 mapping are important imaging tools. The current therapy for AFD is enzyme replacement therapy (ERT), which can reverse or prevent AFD progression, while gene therapy and the use of molecular chaperones represent promising novel therapies for AFD. Anderson-Fabry cardiomyopathy is an important and potentially reversible cause of heart failure that involves LVH, increased susceptibility to arrhythmias and valvular regurgitation. Genetic testing and cardiac MRI are important diagnostic tools, and AFD cardiomyopathy is treatable if ERT is introduced early.
Related Concept Videos
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Pathophysiology of Heart Failure

